Neuroinflammatory paradigms in lysosomal storage diseases

Lysosomal storage diseases (LSDs) include approximately 70 distinct disorders that collectively account for 14% of all inherited metabolic diseases. LSDs are caused by mutations in various enzymes/proteins that disrupt lysosomal function, which impairs macromolecule degradation following endosome-ly...

Full description

Bibliographic Details
Main Authors: Megan Elizabeth Bosch, Tammy eKielian
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-10-01
Series:Frontiers in Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnins.2015.00417/full
id doaj-0c237fc7c18a43919293115c693de546
record_format Article
spelling doaj-0c237fc7c18a43919293115c693de5462020-11-24T22:47:25ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2015-10-01910.3389/fnins.2015.00417167385Neuroinflammatory paradigms in lysosomal storage diseasesMegan Elizabeth Bosch0Tammy eKielian1University of Nebraska Medical CenterUniversity of Nebraska Medical CenterLysosomal storage diseases (LSDs) include approximately 70 distinct disorders that collectively account for 14% of all inherited metabolic diseases. LSDs are caused by mutations in various enzymes/proteins that disrupt lysosomal function, which impairs macromolecule degradation following endosome-lysosome and phagosome-lysosome fusion and autophagy, ultimately disrupting cellular homeostasis. LSDs are pathologically typified by lysosomal inclusions composed of a heterogeneous mixture of various proteins and lipids that can be found throughout the body. However, in many cases the CNS is dramatically affected, which may result from heightened neuronal vulnerability based on their post-mitotic state. Besides intrinsic neuronal defects, another emerging factor common to many LSDs is neuroinflammation, which may negatively impact neuronal survival and contribute to neurodegeneration. Microglial and astrocyte activation is a hallmark of many LSDs that affect the CNS, which often precedes and predicts regions where eventual neuron loss will occur. However, the timing, intensity, and duration of neuroinflammation may ultimately dictate the impact on CNS homeostasis. For example, a transient inflammatory response following CNS insult/injury can be neuroprotective, as glial cells attempt to remove the insult and provide trophic support to neurons. However, chronic inflammation, as seen in several LSDs, can promote neurodegeneration by creating a neurotoxic environment due to elevated levels of cytokines, chemokines, and pro-apoptotic molecules. Although neuroinflammation has been reported in several LSDs, the cellular basis and mechanisms responsible for eliciting neuroinflammatory pathways are just beginning to be defined. This review highlights the role of neuroinflammation in select LSDs and its potential contribution to neuron loss.http://journal.frontiersin.org/Journal/10.3389/fnins.2015.00417/fullAstrocytesMicrogliaNeuroinflammationlysosomal storage diseaseDanger-associated molecular patterns
collection DOAJ
language English
format Article
sources DOAJ
author Megan Elizabeth Bosch
Tammy eKielian
spellingShingle Megan Elizabeth Bosch
Tammy eKielian
Neuroinflammatory paradigms in lysosomal storage diseases
Frontiers in Neuroscience
Astrocytes
Microglia
Neuroinflammation
lysosomal storage disease
Danger-associated molecular patterns
author_facet Megan Elizabeth Bosch
Tammy eKielian
author_sort Megan Elizabeth Bosch
title Neuroinflammatory paradigms in lysosomal storage diseases
title_short Neuroinflammatory paradigms in lysosomal storage diseases
title_full Neuroinflammatory paradigms in lysosomal storage diseases
title_fullStr Neuroinflammatory paradigms in lysosomal storage diseases
title_full_unstemmed Neuroinflammatory paradigms in lysosomal storage diseases
title_sort neuroinflammatory paradigms in lysosomal storage diseases
publisher Frontiers Media S.A.
series Frontiers in Neuroscience
issn 1662-453X
publishDate 2015-10-01
description Lysosomal storage diseases (LSDs) include approximately 70 distinct disorders that collectively account for 14% of all inherited metabolic diseases. LSDs are caused by mutations in various enzymes/proteins that disrupt lysosomal function, which impairs macromolecule degradation following endosome-lysosome and phagosome-lysosome fusion and autophagy, ultimately disrupting cellular homeostasis. LSDs are pathologically typified by lysosomal inclusions composed of a heterogeneous mixture of various proteins and lipids that can be found throughout the body. However, in many cases the CNS is dramatically affected, which may result from heightened neuronal vulnerability based on their post-mitotic state. Besides intrinsic neuronal defects, another emerging factor common to many LSDs is neuroinflammation, which may negatively impact neuronal survival and contribute to neurodegeneration. Microglial and astrocyte activation is a hallmark of many LSDs that affect the CNS, which often precedes and predicts regions where eventual neuron loss will occur. However, the timing, intensity, and duration of neuroinflammation may ultimately dictate the impact on CNS homeostasis. For example, a transient inflammatory response following CNS insult/injury can be neuroprotective, as glial cells attempt to remove the insult and provide trophic support to neurons. However, chronic inflammation, as seen in several LSDs, can promote neurodegeneration by creating a neurotoxic environment due to elevated levels of cytokines, chemokines, and pro-apoptotic molecules. Although neuroinflammation has been reported in several LSDs, the cellular basis and mechanisms responsible for eliciting neuroinflammatory pathways are just beginning to be defined. This review highlights the role of neuroinflammation in select LSDs and its potential contribution to neuron loss.
topic Astrocytes
Microglia
Neuroinflammation
lysosomal storage disease
Danger-associated molecular patterns
url http://journal.frontiersin.org/Journal/10.3389/fnins.2015.00417/full
work_keys_str_mv AT meganelizabethbosch neuroinflammatoryparadigmsinlysosomalstoragediseases
AT tammyekielian neuroinflammatoryparadigmsinlysosomalstoragediseases
_version_ 1725681720653512704